KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to -$37.2 million.

  • Alnylam Pharmaceuticals' Cash from Investing Activities rose 2975.62% to -$37.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $436.3 million, marking a year-over-year increase of 47344.15%. This contributed to the annual value of $436.3 million for FY2025, which is 47344.15% up from last year.
  • Alnylam Pharmaceuticals' Cash from Investing Activities amounted to -$37.2 million in Q4 2025, which was up 2975.62% from $501.1 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $501.1 million during Q3 2025, with a 5-year trough of -$413.4 million in Q4 2021.
  • In the last 5 years, Alnylam Pharmaceuticals' Cash from Investing Activities had a median value of -$33.7 million in 2024 and averaged -$6.0 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 77500.99% in 2021, then surged by 175655.21% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Cash from Investing Activities stood at -$413.4 million in 2021, then soared by 66.16% to -$139.9 million in 2022, then plummeted by 72.01% to -$240.7 million in 2023, then skyrocketed by 78.01% to -$52.9 million in 2024, then grew by 29.76% to -$37.2 million in 2025.
  • Its Cash from Investing Activities was -$37.2 million in Q4 2025, compared to $501.1 million in Q3 2025 and -$141.4 million in Q2 2025.